chevron_leftBack
As of 24 April 2025, Shanghai Henlius Biotech, Inc. has a market cap of $2.64B USD, ranking #4463 globally and #892 in China. It ranks #401 in the Healthcare sector, and #93 in the Biotechnology industry.
Key Stats
Market Cap
$2.64BUSD
20.49B HKD
Enterprise Value
$3.03BUSD
23.51B HKD
Revenue (TTM)
$785.22MUSD
6.09B HKD
EBITDA (TTM)
$159.36MUSD
1.24B HKD
Net Income (TTM)
$112.54MUSD
873.12M HKD
EBITDA Margin
20%
Profit Margin
14%
PE Ratio
23.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jun Zhu
open_in_new
Employees
3,515
Founded
2010
Website
henlius.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 3.3% | 18% | 24% | 120% | 71% | 147% |
Upcoming Earnings
Earnings Date
Tue, May 27
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
2696
上海复宏汉霖生物技术股份有限公司 Class H
ISIN: CNE100003N76
Shares Out.:
Shares Outstanding:
163.429M1
Shares Float:
48.867M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
38.95 HKD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Shanghai Henlius Biotech, Inc.
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops : HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma and limited-stage small cell lung cancer. HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. The company was founded in 2010 and is headquartered in Shanghai, China.
